Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expected developments in hepatology.

Xavier Forns1, José M Sánchez Tapias, Albert Parés

  • 1Liver Unit, Hospital Clínic, Institut d'Investigaciones Biomédiques August Pi i Sunyer, University of Barcelona, Spain.

Best Practice & Research. Clinical Gastroenterology
|December 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026
Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026
Same author

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal of hepatology·2025
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025
Same author

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Journal of hepatology·2025
Same author

Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

The Lancet regional health. Europe·2025
Same journal

Needle-based confocal laser endomicroscopy and artificial intelligence in pancreatic cystic lesions: Insights and clinical advances.

Best practice & research. Clinical gastroenterology·2026
Same journal

Evidence-based approach to the diagnosis, management and surveillance of pancreatic cystic lesions: from the guidelines to the clinical practice.

Best practice & research. Clinical gastroenterology·2026
Same journal

Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound.

Best practice & research. Clinical gastroenterology·2026
Same journal

Predictive risk models for the diagnosis and cancer progression of pancreatic cysts.

Best practice & research. Clinical gastroenterology·2026
Same journal

Preface.

Best practice & research. Clinical gastroenterology·2026
Same journal

Endoscopic ultrasound-guided treatment of pancreatic lesions.

Best practice & research. Clinical gastroenterology·2026
See all related articles

This review analyzes key hepatology issues, including occult hepatitis B virus infection, hepatitis C virus progression, and chronic cholestasis. It highlights advancements in understanding hepatocellular carcinoma pathogenesis and prevention strategies.

Area of Science:

  • Hepatology
  • Viral Hepatitis
  • Chronic Liver Disease
  • Hepatocellular Carcinoma
  • Cholestasis

Background:

  • Predicting new developments in hepatology is challenging, necessitating analysis of critical clinical issues.
  • Occult hepatitis B virus infection, hepatitis C virus natural history, and chronic cholestasis are significant concerns in liver disease management.
  • Hepatocellular carcinoma pathogenesis and prevention require ongoing investigation.

Purpose of the Study:

  • To analyze key issues in chronic hepatitis, including occult hepatitis B virus infection and hepatitis C virus progression.
  • To review advancements in understanding chronic cholestasis, primary biliary cirrhosis, and primary sclerosing cholangitis.
  • To discuss progress in hepatocellular carcinoma, including carcinogenesis, risk factors, prevention, and therapeutic strategies.

Related Experiment Videos

Main Methods:

  • Review of current literature on hepatitis B virus (HBV) infection, including occult infections, genotyping, and antiviral treatments.
  • Analysis of hepatitis C virus (HCV) infection natural history, fibrosis progression, and current/future treatment strategies, including vaccine development.
  • Examination of primary biliary cirrhosis and primary sclerosing cholangitis, focusing on etiological factors, antibodies, and genetic associations.
  • Evaluation of hepatocellular carcinogenesis, risk factors, prevention, and evidence-based therapeutic strategies for hepatocellular carcinoma.

Main Results:

  • Hepatitis B virus genotyping indicates better prognosis for genotype A than D; new antiviral agents are needed.
  • Hepatitis C virus treatment with pegylated interferon and ribavirin is effective, but a vaccine is a major challenge.
  • Primary biliary cirrhosis may be triggered by infections and other xenobiotics; primary sclerosing cholangitis shows association with TNF-alpha(2) allele.
  • Hepatocellular carcinomas are genetically heterogeneous; risk factors and prevention strategies are analyzed, with new therapies under evaluation.

Conclusions:

  • Understanding occult HBV and HCV progression is crucial for managing chronic hepatitis.
  • Further research into the pathogenesis of chronic cholestasis, particularly primary biliary cirrhosis and primary sclerosing cholangitis, is warranted.
  • Addressing the genetic heterogeneity and identifying etiological factors are key to advancing hepatocellular carcinoma prevention and treatment.